NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop

NURIX THERAPEUTICS INC (NASDAQ:NRIX) reported third-quarter 2025 financial results that fell short of analyst expectations, triggering a negative market response in after-hours trading. The clinical-stage biopharmaceutical company, which specializes in targeted protein degradation therapies, missed both revenue and earnings per share estimates for the quarter ending in 2025.

Financial Performance Versus Estimates

The company's Q3 2025 results showed significant deviations from analyst projections:

• Revenue: Reported $7.89 million versus estimates of $17.07 million
• Non-GAAP EPS: Reported -$1.03 per share compared to estimated -$0.86 per share

The revenue shortfall of approximately $9.18 million represents a substantial miss of nearly 54% below expectations. Similarly, the earnings per share result was 20% worse than analysts had anticipated, indicating higher operational costs or lower revenue recognition than projected for the quarter.

Market Reaction

Following the earnings release, Nurix Therapeutics experienced immediate negative pressure in after-hours trading, with shares declining approximately 7%. This market response reflects investor disappointment with both the top and bottom-line misses. The after-hours movement contrasts with the stock's recent performance, which had shown modest gains over the past month with an increase of approximately 11.5%.

Corporate Developments and Pipeline Updates

Beyond the financial results, Nurix provided significant updates on its clinical development programs. The company announced plans to initiate pivotal trials for bexobrutideg in relapsed/refractory chronic lymphocytic leukemia (CLL) during the second half of 2025. This represents a meaningful advancement in the company's lead program toward potential registration studies.

Additionally, Nurix presented preclinical data for GS-6791 (NX-0479), a novel IRAK4 degrader being developed in collaboration with Gilead Sciences. The data, presented at the European Academy of Dermatology and Venereology Congress 2025, demonstrated potent pathway inhibition and efficacy in a dermatitis model, highlighting progress in the company's partnered pipeline.

Forward-Looking Expectations

Looking ahead, analysts have established expectations for Nurix's future performance. For the full year 2025, analysts project sales of approximately $97.2 million. For the fourth quarter of 2025 specifically, the consensus estimates point to sales of $15.25 million and an earnings per share loss of $0.92. The company's ability to meet these future estimates will depend on execution of its clinical programs and management of its cash reserves, which stood at sufficient levels to fund operations based on previous disclosures.

The clinical development updates provide important context for investors evaluating Nurix's long-term potential, though the immediate financial results have clearly disappointed market participants. The progression of bexobrutideg into pivotal trials represents a significant milestone, while the partnered program with Gilead continues to show promising preclinical data.

For more detailed earnings information and analyst estimates, visit Nurix Therapeutics earnings and estimates page.

Disclaimer: This article presents factual information about Nurix Therapeutics' financial results and should not be considered as investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.